nach oben

Current Bladder Dysfunction Reports

Erschienen in:

01.12.2014 | Neurogenic Bladder (CR Powell, Section Editor)

Long-Term Outcomes Following Bladder Augmentation in Children with Neurogenic Bladder

verfasst von: Alison Keenan, Benjamin Whittam, Rosalie Misseri, Mark Cain

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Bladder augmentation remains the final step in the management of refractory neurogenic bladder (NGB) for many children who have failed medical management. The long-term risks and benefits of augmentation surgery are important to understand when counseling patients about management options and when following augmented patients postoperatively. Benefits of bladder augmentation include improved continence, decreased risk of upper tract deterioration, possibly improved quality of life, and even reduced risk of renal-related mortality. However, risks are not trivial and include the potential need for further surgery, calculi formation, bladder perforation, acid-base disturbances, vitamin B₁₂ deficiency, and possibly malignancy. Therefore, patients considered for augmentation should be well counseled and selected and subsequently must be followed closely by an experienced urologist for the duration of their lives.

McGuire EJ et al. Prognostic value of urodynamic testing in myelodysplastic patients. 1981. J Urol. 2002;167(2 Pt 2):1049–53. discussion 1054.PubMedCrossRef

2.••

Misseri R, Szymanski K, Whittam B, et al. Mortality after bladder augmentation in patients with spina bifida. Innsbruck: Paper presented at 25th annual congress of European Society of Pediatric Urology; 2014. This paper neither reported death from perforation of enterocystoplasty nor new-onset renal failure following enterocystoplasty.

Malakounides G et al. Single centre experience: long term outcomes in spina bifida patients. J Pediatr Urol. 2013;9(5):585–9.PubMedCrossRef

Cher ML, Allen TD. Continence in the myelodysplastic patient following enterocystoplasty. J Urol. 1993;149(5):1103–6.PubMed

Raezer DM, Evans RJ, Shrom SH. Augmentation ileocystoplasty in neuropathic bladder. Urology. 1985;25(1):26–30.PubMedCrossRef

Linder A, Leach GE, Raz S. Augmentation cystoplasty in the treatment of neurogenic bladder dysfunction. J Urol. 1983;129(3):491–3.PubMed

Krishna A, Gough DC, Fishwick J, Bruce J. Ileocystoplasty in children: assessing safety and success. Eur Urol. 1995;27(1):62–6.PubMed

Casale AJ, Metcalfe PD, Kaefer MA, et al. Total continence reconstruction: a comparison to staged reconstruction of neuropathic bowel and bladder. J Urol. 2006;176:1712–5.PubMedCrossRef

Herndon CDA, Rink RC, Shaw MBK, et al. The Indiana experience with artificial urinary sphincter in children and young adults. J Urol. 2003;169:650–4.PubMedCrossRef

10.

Venn SN, Mundy AR. Long-term results of augmentation cystoplasty. Eur Urol. 1998;34 Suppl 1:40–2.PubMedCrossRef

11.

Herschron S, Hewitt R. Patient perspective of long-term outcome of augmentation cystoplasty for neurogenic bladder. Urology. 1998;52:672–8.CrossRef

12.

Krishna A, Gough DC. Evaluation of augmentation cystoplasty in childhood with reference to vesico-ureteric reflux and urinary infection. Br J Urol. 1994;74(4):465–8.PubMedCrossRef

13.

Watanabe T, Rivas DA, Smith R, Staas Jr WE, Chancellor MB. The effect of urinary tract reconstruction on neurologically impaired women previously treated with an indwelling urethral catheter. J Urol. 1996;156(6):1926–8.PubMedCrossRef

14.

MacNeily AE, Morrell J, Secord S. Lower urinary tract reconstruction for spina bifida—does it improve health related quality of life? J Urol. 2005;174:1637–43.PubMedCrossRef

15.

MacNeily AE, Jafari S, Scott H, et al. Behavioral effects of lower urinary tract dysfunction health related quality of life in patients with spina bifida: a prospective assessment before and after lower urinary tract reconstruction. JURO. 2009;182:1984–92.

16.

Joseph DB, Borer JG, De Filippo RE, et al. Autologous cell seeded biodegradable scaffold for augmentation cystoplasty: phase II study in children and adolescents with spina bifida. JURO. 2014;191:1389–95.

17.•

Schaefer M, Kaiser A, Stehr M, et al. Bladder augmentation with small intestinal submucosa leads to unsatisfactory long-term results. J Pediatr Urol. 2013;9:878–83.PubMedCrossRef

18.

Metcalfe PD, Casale AJ, Kaefer MA, et al. Spontaneous bladder perforations: a report of 500 augmentations in children and analysis of risk. J Urol. 2006;175:1466–71.PubMedCrossRef

19.

Flood HD, Malhotra SJ, O’Connell HE, Ritchey MJ, Bloom DA, McGuire EJ. Long-term results and complications using augmentation cystoplasty in reconstructive urology. Neurourol Urodyn. 1995;14(4):297–309.PubMedCrossRef

20.

Bertschy C, Bawab F, Liard A, Valioulis I, Mitrofanoff P. Enterocystoplasty complications in children. A study of 30 cases. Eur J Pediatr Surg. 2000;10(1):30–4.PubMedCrossRef

21.

Shekarriz B, Upadhyay J, Demirbilek S, Barthold JS, González R. Surgical complications of bladder augmentation: comparison between various enterocystoplasties in 133 patients. Urology. 2000;55(1):123–8.PubMedCrossRef

22.

DeFoor W, Tackett L, Minevich E, Wacksman J, Sheldon C. Risk factors for spontaneous bladder perforation after augmentation cystoplasty. Urology. 2003;62(4):737–41.PubMedCrossRef

23.

Elder JS, Snyder HM, Hulbert WC, Duckett JW. Perforation of the augmented bladder in patients undergoing clean intermittent catheterization. J Urol. 1988;140(5 Pt 2):1159–62.PubMed

24.

Rushton HG, Woodard JR, Parrott TS, Jeffs RD, Gearhart JP. Delayed bladder rupture after augmentation enterocystoplasty. J Urol. 1988;140(2):344–6.PubMed

25.

Anderson PA, Rickwood AM. Detrusor hyper-reflexia as a factor in spontaneous perforation of augmentation cystoplasty for neuropathic bladder. Br J Urol. 1991;67(2):210–2.PubMedCrossRef

26.

Crane JM, Scherz HS, Billman GF, Kaplan GW. Ischemic necrosis: a hypothesis to explain the pathogenesis of spontaneously ruptured enterocystoplasty. J Urol. 1991;146(1):141–4.PubMed

27.

Rosen MA, Light JK. Spontaneous bladder rupture following augmentation enterocystoplasty. J Urol. 1991;146(5):1232–4.PubMed

28.

Bauer SB, Hendren WH, Kozakewich H, Maloney S, Colodny AH, Mandell J, et al. Perforation of the augmented bladder. J Urol. 1992;148(2 Pt 2):699–703.PubMed

29.

Pope JC, Albers P, Rink RC, Casale AJ, Cain MP, Adams MC, et al. Spontaneous rupture of the augmented bladder: from silence to chaos. Istanbul: Paper presented at 10th annual congress of European Society of Pediatric Urology; 1999.

30.

Yerkes EB, Rink RC, Cain MP, et al. Shunt infection and malfunction after augmentation cystoplasty. JURO. 2001;165:2262–4.

31.

Blyth B, Ewalt DH, Duckett JW, Snyder 3rd HM. Lithogenic properties of enterocystoplasty. J Urol. 1992;148(2 Pt 2):575–7. discussion 578–9.PubMed

32.

Palmer LS, Franco I, Reda EF, Kogan SJ, Levitt SB. Endoscopic management of bladder calculi following augmentation cystoplasty. Urology. 1994;44(6):902–4.PubMedCrossRef

33.

Mathoera RB, Kok DJ, Nijman RJ. Bladder calculi in augmentation cystoplasty in children. Urology. 2000;56(3):482–7.PubMedCrossRef

34.

DeFoor W, Minevich E, Reddy P, Sekhon D, Polsky E, Wacksman J, et al. Bladder calculi after augmentation cystoplasty: risk factors and prevention strategies. J Urol. 2004;172(5 Pt 1):1964–6.PubMedCrossRef

35.

Kaefer M, Hendren WH, Bauer SB, Goldenblatt P, Peters CA, Atala A, et al. Reservoir calculi: a comparison of reservoirs constructed from stomach and other enteric segments. J Urol. 1998;160(6 Pt 1):2187–90.PubMed

36.

Kronner KM, Casale AJ, Cain MP, Zerin MJ, Keating MA, Rink RC. Bladder calculi in the pediatric augmented bladder. J Urol. 1998;160(3 Pt 2):1096–8.PubMedCrossRef

37.

Khoury AE, Salomon M, Doche R, Soboh F, Ackerley C, Jayanthi R, et al. Stone formation after augmentation cystoplasty: the role of intestinal mucus. J Urol. 1997;158(3 Pt 2):1133–7.PubMed

38.

Clark T, Pope IV JC, Adams MC, Wells N, Brock 3rd JW, et al. Factors that influence outcomes of the Mitrofanoff and Malone antegrade continence enema reconstructive procedures in children. J Urol. 2002;168(4 Pt 1):1537–40. discussion 1540.PubMedCrossRef

39.

Misseri R, Szymanski K, Whittam B, et al. Infectious bladder stones after bladder augmentation are not what they seem. Innsbruck: Paper presented at 25th annual congress of European Society of Pediatric Urology; 2014.

40.

Salah MA, Holman E, Khan AM, Toth C. Percutaneous cystolithotomy for pediatric endemic bladder stone: experience with 155 cases from 2 developing countries. J Pediatr Surg. 2005;40(10):1628–31.PubMedCrossRef

41.

Rhee AC, Cain MP. Percutaneous cystolithotomy in the pediatric neuropathic bladder with laparoscopic trocar access: a modified approach useful for the augmented and native bladder, and continent urinary reservoir. J Pediatr Urol. 2013;9(3):289–92.PubMedCrossRef

42.••

Szymanski KM, Misseri R, Whittam B, Amstutz S, Kaefer M, Rink RC, et al. Cutting for stone in augmented bladders: what is the risk of recurrence and is it impacted by treatment modality? J Urol. 2013. (epub ahead of print). One of the major risks following augmentation is bladder stones. This paper outlines the risks of bladder stones and the risk of recurrence as well as the type of stones in recurrence.

43.

Mingin GC, Nguyen HT, Mathias RS, Shepherd JA, Glidden D, Baskin LS. Growth and metabolic consequences of bladder augmentation in children with myelomeningocele and bladder exstrophy. Pediatrics. 2002;110(6):1193–8.PubMedCrossRef

44.

Hafez AT, McLorie G, Gilday D, Laudenberg B, Upadhyay J, Bagli D, et al. Long-term evaluation of metabolic profile and bone mineral density after ileocystoplasty in children. J Urol. 2003;170(4 Pt 2):1639–41.PubMedCrossRef

45.

Koch MO, McDougal WS, Thompson CO. Mechanisms of solute transport following urinary diversion through intestinal segments: an experimental study with rats. J Urol. 1991;146(5):1390–4.PubMed

46.

Dahl DM, McDougal WS. Use of intestinal segments in urinary diversion. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. Philadelphia: Saunders Elsevier; 2007.

47.

Mingin G, Maroni P, Gerharz EW, Woodhouse CR, Baskin LS. Linear growth after enterocystoplasty in children and adolescents: a review. World J Urol. 2004;22(3):196–9.PubMedCrossRef

48.

Stein R, Schröder A, Thüroff JW. Bladder augmentation and urinary diversion in patients with neurogenic bladder: non-surgical considerations. J Pediatr Urol. 2012;8(2):145–52.PubMedCrossRef

49.

Richards P, Chamberlain MJ, Wrong OM. Treatment of osteomalacia of renal tubular acidosis by sodium bicarbonate alone. Lancet. 1972;2(7785):994–7.PubMedCrossRef

50.

Siklos P, Davie M, Jung RT, Chalmers TM. Osteomalacia in ureterosigmoidostomy: healing by correction of the acidosis. Br J Urol. 1980;52(1):61–2.PubMedCrossRef

51.

Perry W, Allen LN, Stamp TC, Walker PG. Vitamin D resistance in osteomalacia after ureterosigmoidostomy. N Engl J Med. 1977;297(20):1110–2.PubMedCrossRef

52.

Lindenbaum J, Healton EB, Savage DG, Brust JC, Garrett TJ, Podell ER, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med. 1988;318(26):1720–8.PubMedCrossRef

53.

Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J. Neurologic aspects of cobalamin deficiency. Medicine (Baltimore). 1991;70(4):229–45.CrossRef

54.

Rosenbaum DH, Cain MP, Kaefer M, et al. Ileal enterocystoplasty and B12 deficiency in pediatric patients. J Urol. 2008;179:1544–8.PubMedCrossRef

55.

Blackburn SC, Parkar S, Prime M, Healiss L, Desai D, Mustaq I, et al. Ileal bladder augmentation and vitamin B12: levels decrease with time after surgery. J Pediatr Urol. 2012;8(1):47–50.PubMedCrossRef

56.

Vanderbrink BA, Cain MP, King S, Meldrum K, Kaefer M, Misseri R, et al. Is oral vitamin B(12) therapy effective for vitamin B(12) deficiency in patients with prior ileocystoplasty? J Urol. 2010;184(4):1781–5.PubMedCrossRef

57.

Keenan AC, Whittam BM, Rink R, Kaefer M, Misseri R, King S, Cain MP. Vitamin B12 deficiency in patients with prior enterocystoplasty. Manuscript in review 2014.

58.

Golomb J, Klutke CG, Lewin KJ, Goodwin WE, de Kernion JB, Raz S. Bladder neoplasms associated with augmentation cystoplasty: report of 2 cases and literature review. J Urol. 1989;142(2 Pt 1):377–80.PubMed

59.

Nurse DE, Mundy AR. Assessment of the malignant potential of cystoplasty. Br J Urol. 1989;64(5):489–92.PubMedCrossRef

60.

Filmer RB, Spencer JR. Malignancies in bladder augmentations and intestinal conduits. J Urol. 1990;143(4):671–8.PubMed

61.

Barrington JW, Fulford S, Griffiths D, Stephenson TP. Tumors in bladder remnant after augmentation enterocystoplasty. J Urol. 1997;157(2):482–5. discussion 485–6.PubMedCrossRef

62.

Lane T, Shah J. Carcinoma following augmentation ileocystoplasty. Urol Int. 2000;64(1):31–2.PubMedCrossRef

63.

Soergel TM, Cain MP, Misseri R, Gardner TA, Koch MO, Rink RC. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol. 2004;172(4 Pt 2):1649–51.PubMedCrossRef

64.

Castellan M, Gosalbez R, Perez-Brayfield M, Healey P, McDonald R, Labbie A, et al. Tumor in bladder reservoir after gastrocystoplasty. J Urol. 2007;178(4 Pt 2):1771–4. discussion 1774.PubMedCrossRef

65.

Balachandra B, Swanson P, Upton M, Yeh M. Adenocarcinoma arising in a gastrocystoplasty. J Clin Pathol. 2007;60(1):85–7.PubMedCentralPubMedCrossRef

66.

Vemulakonda VM, Lendvay TS, Shnorhavorian M, Joyner BD, Kaplan H, Mitchell ME, et al. Metastatic adenocarcinoma after augmentation gastrocystoplasty. J Urol. 2008;179(3):1094–6. discussion 1097.PubMedCrossRef

67.

Husmann DA, Rathbun SR. Long-term follow up of enteric bladder augmentations: the risk for malignancy. J Pediatr Urol. 2008;4(5):381–5. discussion 386.PubMedCrossRef

68.•

Higuchi TT, Granberg CF, Fox JA, Husmann DA. Augmentation cystoplasty and risk of neoplasia: fact, fiction and controversy. J Urol. 2010;184(6):2492–6.PubMedCrossRef

69.

Harzmann R, Weckermann D. Problem of secondary malignancy after urinary diversion and enterocystoplasty. Scand J Urol Nephrol. 1992;142:56.

70.

Metcalfe PD, Rink RC. Bladder augmentation: complications in the pediatric population. Curr Urol Rep. 2007;8(2):152–6.PubMedCrossRef

71.

Gepi-Attee S, Ganabathi K, Abrams PH, et al. Villous adenoma in augmentation colocystoplasty: a case report and discussion of the pathogenesis. J Urol. 1992;147(1):128–30.PubMed

72.

Gerharz EW, Turner WH, Kalble T, Woodhouse CR. Metabolic and functional consequences of urinary reconstruction with bowel. BJU Int. 2003;91(2):143–9.PubMedCrossRef

73.••

Higuchi TT, Fox JA, Husmann DA. Annual endoscopy and urine cytology for the surveillance of bladder tumors after enterocystoplasty for congenital bladder anomalies. J Urol. 2011;186(5):1791–5. This paper offers current practice recommendations for screening for malignancy following enterocystoplasty. PubMedCrossRef

74.

Kokorowski PJ et al. Screening for malignancy after augmentation cystoplasty in children with spina bifida: a decision analysis. J Urol. 2011;186(4):1437–43.PubMedCrossRef

75.

Austin JC, Elliott S, Cooper CS. Patients with spina bifida and bladder cancer: atypical presentation, advanced stage and poor survival. J Urol. 2007;178:798–801.PubMedCrossRef

Titel: Long-Term Outcomes Following Bladder Augmentation in Children with Neurogenic Bladder
verfasst von: Alison Keenan
Benjamin Whittam
Rosalie Misseri
Mark Cain
Publikationsdatum: 01.12.2014
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 4/2014
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-014-0268-1

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Stress Urinary Incontinence in the Elderly: Evaluation, Surgical Treatment, and Management of Postoperative Voiding Dysfunction

Is the Diabetic Bladder a Neurogenic Bladder? Evidence from the Literature

Medical Therapy in Overactive Bladder of the Elderly

Nocturia in the Elderly